aTyr Pharma Reports $190,000 Revenue in Q3 2025, Faces $25.7 Million Net Loss

aTyr Pharma, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $190,000, a significant increase from zero revenue in the same period last year. For the nine months ended September 30, 2025, the company generated $190,000 in revenue, down from $235,000 in the prior year. The revenue primarily stemmed from a collaboration agreement with Kyorin Pharmaceutical Co., Ltd., which involved drug product material sold to support analytical method validation in Japan. Despite this revenue, aTyr Pharma continued to experience substantial net losses, reporting a consolidated net loss of $25.7 million for the quarter and $60.2 million for the nine-month period, compared to losses of $17.3 million and $49.1 million, respectively, in the prior year.

The company's operating expenses for the third quarter totaled $26.9 million, up from $18.1 million in the same quarter of 2024. This increase was driven by higher research and development costs, which rose to $22.1 million from $14.8 million, largely due to increased manufacturing costs associated with preparations for a potential Biologics License Application (BLA) filing for its lead candidate, efzofitimod. General and administrative expenses also increased to $4.8 million from $3.3 million, reflecting higher personnel-related costs and professional fees. The total operating expenses for the nine months ended September 30, 2025, were $63.0 million, compared to $52.3 million in the same period of 2024.

In terms of strategic developments, aTyr Pharma has been actively advancing its clinical programs, particularly for efzofitimod, which is in development for interstitial lung disease (ILD). The company recently announced top-line data from a Phase 3 clinical trial, the EFZO-FIT study, which did not meet its primary endpoint but showed clinically meaningful improvements in secondary outcomes. The company plans to meet with the FDA in early 2026 to discuss the results and potential next steps. Additionally, aTyr Pharma has been leveraging its Jefferies ATM Offering Program, raising approximately $66.4 million through the sale of common stock during the nine months ended September 30, 2025.

As of September 30, 2025, aTyr Pharma reported total assets of $106.7 million, an increase from $96.8 million at the end of 2024. The company had cash and cash equivalents of $6.2 million, down from $11.1 million at the end of the previous year. The decrease in cash is attributed to ongoing operational expenses, although the company also holds $84.1 million in available-for-sale investments. The total stockholders' equity increased to $80.0 million from $69.8 million, reflecting the issuance of common stock under the ATM program.

Looking ahead, aTyr Pharma anticipates continued net losses as it progresses through clinical development and prepares for potential commercialization of efzofitimod. The company expects to require substantial additional capital to fund its operations, which may be raised through equity offerings, collaborations, or licensing arrangements. The management remains focused on advancing its clinical programs while navigating the financial challenges associated with being a clinical-stage biotechnology company.